KR102703122B1 - 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법 - Google Patents

소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법 Download PDF

Info

Publication number
KR102703122B1
KR102703122B1 KR1020187028361A KR20187028361A KR102703122B1 KR 102703122 B1 KR102703122 B1 KR 102703122B1 KR 1020187028361 A KR1020187028361 A KR 1020187028361A KR 20187028361 A KR20187028361 A KR 20187028361A KR 102703122 B1 KR102703122 B1 KR 102703122B1
Authority
KR
South Korea
Prior art keywords
troxacitabine
sorafenib
phosphoramidate prodrug
administered
regorafenib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028361A
Other languages
English (en)
Korean (ko)
Other versions
KR20180118745A (ko
Inventor
마크 알브레텔라
안데르스 이안로트
비요른 클라슨
프레드리크 오버그
존 오드
Original Assignee
메디비르 아크티에보라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디비르 아크티에보라그 filed Critical 메디비르 아크티에보라그
Publication of KR20180118745A publication Critical patent/KR20180118745A/ko
Application granted granted Critical
Publication of KR102703122B1 publication Critical patent/KR102703122B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020187028361A 2016-03-02 2017-02-28 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법 Active KR102703122B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1650274-2 2016-03-02
SE1650274 2016-03-02
SE1651204-8 2016-09-08
SE1651204 2016-09-08
PCT/SE2017/050186 WO2017151044A1 (en) 2016-03-02 2017-02-28 Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Publications (2)

Publication Number Publication Date
KR20180118745A KR20180118745A (ko) 2018-10-31
KR102703122B1 true KR102703122B1 (ko) 2024-09-04

Family

ID=59744330

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028361A Active KR102703122B1 (ko) 2016-03-02 2017-02-28 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법

Country Status (17)

Country Link
US (2) US10456413B2 (https=)
EP (1) EP3423061B1 (https=)
JP (1) JP6968080B2 (https=)
KR (1) KR102703122B1 (https=)
CN (2) CN111956646B (https=)
AU (2) AU2017227516B2 (https=)
CA (1) CA3014769C (https=)
ES (1) ES2987989T3 (https=)
HR (1) HRP20241508T1 (https=)
HU (1) HUE068940T2 (https=)
MY (1) MY198140A (https=)
PL (1) PL3423061T3 (https=)
RS (1) RS66090B1 (https=)
RU (1) RU2018134336A (https=)
SG (1) SG11201806855WA (https=)
WO (1) WO2017151044A1 (https=)
ZA (1) ZA201805445B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
EP3747433A4 (en) 2018-02-02 2021-12-22 Cafa Therapeutics Limited COMBINATION OF CELL IMMUNOTHERAPY
JP7337539B2 (ja) 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
HUE071473T2 (hu) * 2020-04-15 2025-09-28 Medivir Ab MIV-818/lenvatinib kombinációs terápia májrák kezelésére
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물
IT202000022636A1 (it) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20090098137A1 (en) * 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CN102190616B (zh) 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
CN103570613B (zh) 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 氘代ω-二苯基脲或其盐的多晶型物
JP6342392B2 (ja) 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
WO2014047199A1 (en) * 2012-09-19 2014-03-27 The Research Foundation For The State University Of New York Novel prodrugs for selective anticancer therapy
CN105934438A (zh) * 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CA3014769C (en) 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection

Also Published As

Publication number Publication date
AU2017227516A1 (en) 2018-08-30
JP2019507764A (ja) 2019-03-22
RU2018134336A (ru) 2020-04-02
ZA201805445B (en) 2019-07-31
CN109069509A (zh) 2018-12-21
EP3423061A4 (en) 2019-11-13
CN111956646B (zh) 2023-07-25
CA3014769C (en) 2024-01-09
EP3423061A1 (en) 2019-01-09
WO2017151044A1 (en) 2017-09-08
EP3423061C0 (en) 2024-08-07
AU2017227516B2 (en) 2022-03-03
KR20180118745A (ko) 2018-10-31
US10456413B2 (en) 2019-10-29
PL3423061T3 (pl) 2024-12-16
CN111956646A (zh) 2020-11-20
ES2987989T3 (es) 2024-11-18
US20190091246A1 (en) 2019-03-28
HUE068940T2 (hu) 2025-02-28
AU2022203761A1 (en) 2022-06-16
EP3423061B1 (en) 2024-08-07
AU2022203761B2 (en) 2024-06-13
BR112018067387A2 (pt) 2019-01-02
MY198140A (en) 2023-08-07
HRP20241508T1 (hr) 2025-01-03
US20200009166A1 (en) 2020-01-09
SG11201806855WA (en) 2018-09-27
CA3014769A1 (en) 2017-09-08
US10960017B2 (en) 2021-03-30
RU2018134336A3 (https=) 2020-05-22
CN109069509B (zh) 2020-10-16
JP6968080B2 (ja) 2021-11-17
RS66090B1 (sr) 2024-11-29

Similar Documents

Publication Publication Date Title
KR102703122B1 (ko) 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법
US20190160066A1 (en) Therapeutic agent for lung cancer that has acquired egfr-tki resistance
WO2017037292A1 (en) Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer
JP2019514864A (ja) 肝癌の治療方法
EP4135849B1 (en) Miv-818/lenvatinib combination therapy for liver cancer
SG191926A1 (en) Combinations
JP2022532189A (ja) 軟部肉腫の併用療法用キノリン誘導体
HK40040637A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40040637B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
HK40000353A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353B (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer
TWI447111B (zh) Antitumor agents or postoperative adjuvant chemotherapeutic agents for hepatocellular carcinoma treatment
BR112018067387B1 (pt) Uso de um agente terapêutico

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181001

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240402

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240609

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240902

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240902

End annual number: 3

Start annual number: 1

PG1601 Publication of registration